Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
173 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015', provides an overview of the Cytomegalovirus (HHV-5) Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cytomegalovirus (HHV-5) Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cytomegalovirus (HHV-5) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cytomegalovirus (HHV-5) Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cytomegalovirus (HHV-5) Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Cytomegalovirus (HHV-5) Infections Overview 9 Therapeutics Development 10 Pipeline Products for Cytomegalovirus (HHV-5) Infections - Overview 10 Pipeline Products for Cytomegalovirus (HHV-5) Infections - Comparative Analysis 11 Cytomegalovirus (HHV-5) Infections - Therapeutics under Development by Companies 12 Cytomegalovirus (HHV-5) Infections - Therapeutics under Investigation by Universities/Institutes 15 Cytomegalovirus (HHV-5) Infections - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Cytomegalovirus (HHV-5) Infections - Products under Development by Companies 20 Cytomegalovirus (HHV-5) Infections - Products under Investigation by Universities/Institutes 23 Cytomegalovirus (HHV-5) Infections - Companies Involved in Therapeutics Development 24 AIMM Therapeutics B.V. 24 Altor BioScience Corporation 25 Applied Immune Technologies Ltd 26 Astellas Pharma Inc. 27 Atara Biotherapeutics, Inc. 28 Bionor Pharma ASA 29 Biotest AG 30 CAP-CMV GmbH 31 Cell Medica Limited 32 Chimerix, Inc. 33 China Biologic Products, Inc. 34 CyTuVax B.V. 35 GlaxoSmithKline Plc 36 Hookipa Biotech AG 37 Humabs BioMed SA 38 iQur Limited 39 Kadmon Corporation, LLC 40 Lead Discovery Center GmbH 41 Merck & Co., Inc. 42 Microbiotix, Inc. 43 Novartis AG 44 Pfizer Inc. 45 Phoenix Biotechnology, Inc. 46 Savoy Pharmaceuticals, Inc. 47 Trellis Bioscience, Inc. 48 Vakzine Projekt Management GmbH 49 VBI Vaccines Inc. 50 Vical Incorporated 51 Cytomegalovirus (HHV-5) Infections - Therapeutics Assessment 52 Assessment by Monotherapy Products 52 Assessment by Combination Products 53 Assessment by Target 54 Assessment by Mechanism of Action 56 Assessment by Route of Administration 58 Assessment by Molecule Type 60 Drug Profiles 62 AL-18 - Drug Profile 62 Antibodies to Inhibit HLA-A2 for Cytomegalovirus Infections - Drug Profile 63 Antibody for Human Cytomegalovirus Infection - Drug Profile 64 Antiviral TCR-Ck - Drug Profile 65 Antiviral TCR-Ig - Drug Profile 66 ASP-0113 - Drug Profile 67 brincidofovir - Drug Profile 69 BT-084 - Drug Profile 72 CAPCMV-001 - Drug Profile 73 Cell Therapy 3 For CMV - Drug Profile 74 Cell Therapy for CMV Infections - Drug Profile 75 Cell Therapy for Cytomegalovirus (HHV-5) Infections - Drug Profile 76 Cell Therapy for Cytomegalovirus Infections - Drug Profile 77 Cell Therapy for Cytomegalovirus Infections - Drug Profile 78 Cell Therapy for Cytomegalovirus Infections and GBM - Drug Profile 79 Cell Therapy for Infectious Disease - Drug Profile 80 Cell Therapy for Infectious Diseases - Drug Profile 81 Cell Therapy for Viral Infections Post-HSCT - Drug Profile 82 Cell Therapy to Target PP65 for Cytomegalovirus Infections - Drug Profile 83 Cell Therapy to Target PP65 for Cytomegalovirus Infections - Drug Profile 85 Cellular Immunotherapy for Viral Infections - Drug Profile 86 CMX-669 - Drug Profile 87 CSJ-148 - Drug Profile 88 CyMVectin - Drug Profile 89 Cytomegalovirus (virus like particles) vaccine - Drug Profile 90 Cytomegalovirus vaccine - Drug Profile 91 Cytomegalovirus vaccine - Drug Profile 92 Cytomegalovirus vaccine - Drug Profile 93 Cytomegalovirus vaccine - Drug Profile 94 Cytomegalovirus vaccine 1 - Drug Profile 95 Cytomegalovirus vaccine 2 - Drug Profile 97 Cytovir-CMV - Drug Profile 98 Dendritic Cell Therapyto Target CMV Antigen for Cytomegalovirus Infections - Drug Profile 100 Drug for Cytomegalovirus - Drug Profile 101 filociclovir - Drug Profile 102 Gene Therapy for Cytomegalovirus Infections - Drug Profile 104 HB-101 - Drug Profile 105 LDC-4297 - Drug Profile 106 letermovir - Drug Profile 107 maribavir - Drug Profile 108 MBX-2168 - Drug Profile 110 Monoclonal Antibody for Cytomegalovirus Infections - Drug Profile 111 Monoclonal Antibody for HCMV Infections - Drug Profile 112 Peptides to Inhibit Heparan Sulfate for HHV-5 Infections - Drug Profile 113 RBT-301 - Drug Profile 114 Recombinant Peptide for Infectious Diseases - Drug Profile 115 RKP-00156 - Drug Profile 116 Small Molecule 1 for Human Cytomegalovirus Infection - Drug Profile 117 Small Molecule 2 for Human Cytomegalovirus Infection - Drug Profile 118 Small Molecule 3 for Human Cytomegalovirus Infection - Drug Profile 119 Small Molecules for CMV Infections - Drug Profile 120 Small Molecules for Viral Infections - Drug Profile 121 Small Molecules to Activate Sirtuin for Viral Infections - Drug Profile 122 Small Molecules to Inhibit Acetyl-CoA Carboxylase for CMV Infections - Drug Profile 123 Small Molecules to Inhibit Cyclin-Dependent Kinase 7 for Oncology, Inflammation and Infectious Diseases - Drug Profile 124 Small Molecules to Inhibit Na+/K+ ATPase for Human Cytomegalovirus Infections - Drug Profile 125 TRL-345 - Drug Profile 126 V-160 - Drug Profile 127 Vacc-CMV - Drug Profile 128 Vaccine for Cytomegalovirus Infection and Glioblastoma Multiforme - Drug Profile 129 VBI-1501A - Drug Profile 130 Viralym-C - Drug Profile 131 Viroprev - Drug Profile 132 VPM-2001 - Drug Profile 133 Cytomegalovirus (HHV-5) Infections - Recent Pipeline Updates 134 Cytomegalovirus (HHV-5) Infections - Dormant Projects 154 Cytomegalovirus (HHV-5) Infections - Discontinued Products 158 Cytomegalovirus (HHV-5) Infections - Product Development Milestones 159 Featured News & Press Releases 159 Appendix 168 Methodology 168 Coverage 168 Secondary Research 168 Primary Research 168 Expert Panel Validation 168 Contact Us 168 Disclaimer 169
List of Tables
Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H2 2015 14 Number of Products under Development for Cytomegalovirus (HHV-5) Infections - Comparative Analysis, H2 2015 15 Number of Products under Development by Companies, H2 2015 17 Number of Products under Development by Companies, H2 2015 (Contd..1) 18 Number of Products under Investigation by Universities/Institutes, H2 2015 19 Comparative Analysis by Late Stage Development, H2 2015 20 Comparative Analysis by Clinical Stage Development, H2 2015 21 Comparative Analysis by Early Stage Development, H2 2015 22 Comparative Analysis by Unknown Stage Development, H2 2015 23 Products under Development by Companies, H2 2015 24 Products under Development by Companies, H2 2015 (Contd..1) 25 Products under Development by Companies, H2 2015 (Contd..2) 26 Products under Investigation by Universities/Institutes, H2 2015 27 Cytomegalovirus (HHV-5) Infections - Pipeline by AIMM Therapeutics B.V., H2 2015 28 Cytomegalovirus (HHV-5) Infections - Pipeline by Altor BioScience Corporation, H2 2015 29 Cytomegalovirus (HHV-5) Infections - Pipeline by Applied Immune Technologies Ltd, H2 2015 30 Cytomegalovirus (HHV-5) Infections - Pipeline by Astellas Pharma Inc., H2 2015 31 Cytomegalovirus (HHV-5) Infections - Pipeline by Atara Biotherapeutics, Inc., H2 2015 32 Cytomegalovirus (HHV-5) Infections - Pipeline by Bionor Pharma ASA, H2 2015 33 Cytomegalovirus (HHV-5) Infections - Pipeline by Biotest AG, H2 2015 34 Cytomegalovirus (HHV-5) Infections - Pipeline by CAP-CMV GmbH, H2 2015 35 Cytomegalovirus (HHV-5) Infections - Pipeline by Cell Medica Limited, H2 2015 36 Cytomegalovirus (HHV-5) Infections - Pipeline by Chimerix, Inc., H2 2015 37 Cytomegalovirus (HHV-5) Infections - Pipeline by China Biologic Products, Inc., H2 2015 38 Cytomegalovirus (HHV-5) Infections - Pipeline by CyTuVax B.V., H2 2015 39 Cytomegalovirus (HHV-5) Infections - Pipeline by GlaxoSmithKline Plc, H2 2015 40 Cytomegalovirus (HHV-5) Infections - Pipeline by Hookipa Biotech AG, H2 2015 41 Cytomegalovirus (HHV-5) Infections - Pipeline by Humabs BioMed SA, H2 2015 42 Cytomegalovirus (HHV-5) Infections - Pipeline by iQur Limited, H2 2015 43 Cytomegalovirus (HHV-5) Infections - Pipeline by Kadmon Corporation, LLC, H2 2015 44 Cytomegalovirus (HHV-5) Infections - Pipeline by Lead Discovery Center GmbH, H2 2015 45 Cytomegalovirus (HHV-5) Infections - Pipeline by Merck & Co., Inc., H2 2015 46 Cytomegalovirus (HHV-5) Infections - Pipeline by Microbiotix, Inc., H2 2015 47 Cytomegalovirus (HHV-5) Infections - Pipeline by Novartis AG, H2 2015 48 Cytomegalovirus (HHV-5) Infections - Pipeline by Pfizer Inc., H2 2015 49 Cytomegalovirus (HHV-5) Infections - Pipeline by Phoenix Biotechnology, Inc., H2 2015 50 Cytomegalovirus (HHV-5) Infections - Pipeline by Savoy Pharmaceuticals, Inc., H2 2015 51 Cytomegalovirus (HHV-5) Infections - Pipeline by Trellis Bioscience, Inc., H2 2015 52 Cytomegalovirus (HHV-5) Infections - Pipeline by Vakzine Projekt Management GmbH, H2 2015 53 Cytomegalovirus (HHV-5) Infections - Pipeline by VBI Vaccines Inc., H2 2015 54 Cytomegalovirus (HHV-5) Infections - Pipeline by Vical Incorporated, H2 2015 55 Assessment by Monotherapy Products, H2 2015 56 Assessment by Combination Products, H2 2015 57 Number of Products by Stage and Target, H2 2015 59 Number of Products by Stage and Mechanism of Action, H2 2015 61 Number of Products by Stage and Route of Administration, H2 2015 63 Number of Products by Stage and Molecule Type, H2 2015 65 Cytomegalovirus (HHV-5) Infections Therapeutics - Recent Pipeline Updates, H2 2015 138 Cytomegalovirus (HHV-5) Infections - Dormant Projects, H2 2015 158 Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..1), H2 2015 159 Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..2), H2 2015 160 Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..3), H2 2015 161 Cytomegalovirus (HHV-5) Infections - Discontinued Products, H2 2015 162
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
